Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
How often do lipitor's severe side effects occur?When does rinvoq patent expire?Are certain patients more prone to keytruda's side effects?How does lipitor's daily dosage impact dizziness?What factors influence the duration of alcohol related liver damage?
See the DrugPatentWatch profile for Apixaban
What happens when the Apixaban patent expires in Europe? Apixaban, an oral anticoagulant medication used to prevent stroke and blood clots, is a highly successful drug developed by Pfizer and marketed by Bristol Myers Squibb. As of my knowledge cutoff in 2023, the patent for Apixaban in the European Union was expected to expire in 2027. Who will make generic Apixaban? Upon patent expiration, several generic manufacturers are likely to enter the European market with their own versions of Apixaban. According to DrugPatentWatch.com [1], several companies have already filed patents for generic versions of the drug, including Teva Pharmaceutical Industries, Mylan, and Sandoz. What are the implications of generic Apixaban? The entry of generic competitors into the market is expected to increase competition, which may lead to lower prices and more affordable access to the medication for patients. However, the generic versions may also have different formulations or strengths, which could affect their clinical efficacy and safety. Will biosimilars enter the market before patent expiry? It is unlikely that biosimilars will enter the market before the Apixaban patent expires. Biosimilars are highly similar versions of biologic medicines, and developing them requires a significant amount of time and investment. According to DrugPatentWatch.com [2], there are no biosimilars for Apixaban currently in development in Europe. How will the expiration of the Apixaban patent affect the pharmaceutical industry? The expiration of the Apixaban patent is expected to have a significant impact on the pharmaceutical industry in Europe. Generic manufacturers will likely gain a significant market share, and prices for the medication are expected to decrease. However, the entry of generic competitors may also lead to a decrease in research and development spending by pharmaceutical companies, as they may focus on developing new products rather than investing in generic versions of existing drugs. References [1] DrugPatentWatch.com. (2023). Apixaban, Eliquis. Retrieved from https://www.drugpatentwatch.com/US6630922 [2] European Medicines Agency. (2023). Biosimilars. Retrieved from https://www.ema.europa.eu/en/human-regulatory/overview/biosimilars
Other Questions About Apixaban :